Dr. Halfdanarson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St SW
Rochester, MN 55905Phone+1 507-284-2511Fax+1 507-284-1803
Summary
- Medical Oncologist with a focus on neuroendocrine and GI oncology.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2003 - 2007
University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 2000 - 2003
University of IcelandClass of 1995
Certifications & Licensure
AZ State Medical License 2012 - 2025
MN State Medical License 2015 - 2025
IA State Medical License 2000 - 2013- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Clinical Trials
- Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors Start of enrollment: 2011 Feb 01
- A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Start of enrollment: 2014 Jan 01
- Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Start of enrollment: 2016 Aug 16
Publications & Presentations
PubMed
- 21 citationsA pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma.Daniel H. Ahn, Pedro Luiz Serrano Uson Junior, Peter Masci, Heidi E. Kosiorek, Thorvardur R. Halfdanarson
Investigational New Drugs. 2021-08-31 - 186 citationsThe North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine TumorsJames R. Howe, Nipun B. Merchant, Claudius Conrad, Xavier M. Keutgen, Julie Hallet
Pancreas. 2020-01-01 - 76 citationsThe North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors.Thorvardur R Halfdanarson, Jonathan R Strosberg, Laura Tang, Andrew M Bellizzi, Emily K Bergsland
Pancreas. 2020-08-01
Authored Content
- Borderline Resectable and Locally Advanced Pancreas Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Neoadjuvant Therapy Pathologic Response and Prediction of SurvivalOctober 2020
Press Mentions
Sharing Mayo Clinic: Georgia Man with Neuroendocrine Cancer Gains Quality of Life Thanks to New Nuclear Med TherapyApril 17th, 2022- Georgia Man with Neuroendocrine Cancer Gains Quality of Life Thanks to New Nuclear Med TherapyApril 14th, 2022
- Hyperammonemic Encephalopathy in a Patient with Fibrolamellar Hepatocellular Carcinoma: Case Report and Literature ReviewJanuary 28th, 2019
Professional Memberships
- Member
- Member
- Member
- North American Neuroendocrine Tumor Society (NANETS)Member
- European Neuroendocrine Tumor Society (ENETS)Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
